Eisai Could Have Difficulty Ending Market Deal With Pfizer
This article was originally published in PharmAsia News
Executive SummaryEisai's attempt to extricate itself from a marketing agreement with U.S.-based Pfizer for Eisai's Aricept (donepezil) for treating Alzheimer's disease may not be as easy as it thought. Eisai sought to end the deal after Pfizer announced it would take over another U.S. firm, Wyeth, but Pfizer is resisting the breakup. Eisai contends the merger with Wyeth violates Pfizer's contract with Eisai, so the contract has been nullified. At stake are huge sales commissions Eisai pays to Pfizer to market Eisai's best-selling drug. Eisai says it can do the marketing itself. (Click here for more - a subscription may be required
You may also be interested in...
Corindus Vascular Robotics Inc. expects its CorPath GRX robotic intervention system will eventually be part of a widespread system of "telerobotic" intervention sites operated by specialists located far away. See what Tejas Patel, an interventional cardiologist at the Apex Heart Institute in Ahmedabad, India, said about it here.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.